出版商更正：靶向肝脏谷氨酰胺酶活性以改善高血糖症。

Publisher Correction: Targeting hepatic glutaminase activity to ameliorate hyperglycemia.

作者信息

Miller Russell A, Shi Yuji, Lu Wenyun, Pirman David A, Jatkar Aditi, Blatnik Matthew, Wu Hong, Cárdenas César, Wan Min, Foskett J Kevin, Park Junyoung O, Zhang Yiyi, Holland William L, Rabinowitz Joshua D, Birnbaum Morris J

机构信息

Institute for Diabetes, Obesity, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Pfizer Internal Medicine Research Units, Cambridge, Massachusetts, USA.

出版信息

Nat Med. 2018 Sep;24(9):1482. doi: 10.1038/s41591-018-0047-1.

DOI:10.1038/s41591-018-0047-1

PMID:29895835

Abstract

In the version of this article initially published, the "[13C2]α-ketoglutarate" label on Fig. 1g is incorrect. It should be "[13C5]α-ketoglutarate". Additionally, in Fig. 3b, the "AAV-GFP" group is missing a notation for significance, and in Fig. 3c, the "AAV-GLS2-sh" group is missing a notation for significance. There should be a double asterisk notating significance in both panels. Finally, in the Fig. 4g legend, "[13C6]UDP-glucose" should be "[13C3]UDP-glucose", and in the Fig. 4h legend, "[13C6]hexose" should be "[13C3]hexose". The errors have been corrected in the HTML and PDF versions of this article.

摘要

在本文最初发表的版本中，图1g上的“[13C2]α-酮戊二酸”标签有误。应为“[13C5]α-酮戊二酸”。此外，在图3b中，“AAV-GFP”组缺少显著性标注，在图3c中，“AAV-GLS2-sh”组也缺少显著性标注。两个图中都应有双 asterisk 表示显著性。最后，在图4g的图例中，“[13C6]UDP-葡萄糖”应为“[13C3]UDP-葡萄糖”，在图4h的图例中，“[13C6]己糖”应为“[13C3]己糖”。这些错误已在本文的HTML和PDF版本中得到更正。